FENC Fennec Pharmaceuticals Inc.
Healthcare$9.89-0.40%ClosedMarket Cap: $282.7M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
9.05
P/S
5.56
EV/EBITDA
-36.51
DCF Value
$-7.87
FCF Yield
-2.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
92.2%
Operating Margin
-11.0%
Net Margin
-16.4%
ROE
-55.1%
ROA
-11.7%
ROIC
-9.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $15.1M | 96.2% | $-119.0K | $201.0K | $— | — |
| Q4 null | $13.8M | 87.2% | $-2.6M | $-4.8M | $— | — |
| FY null | $44.6M | 91.6% | $-6.3M | $-9.7M | $— | — |
| Q3 null | $12.5M | 94.7% | $-201.0K | $-638.0K | $— | — |
| Q2 null | $9.7M | 90.0% | $-2.7M | $-3.2M | $— | — |
| Q1 null | $8.8M | 95.7% | $-821.0K | $-1.2M | $— | — |
| Q4 null | $7.9M | 91.6% | $-959.0K | $-2.0M | $— | — |
| FY null | $47.5M | 93.3% | $2.5M | $-436.0K | $— | — |
| Q3 null | $7.0M | 80.5% | $-5.2M | $-5.7M | $— | — |
| Q2 null | $7.3M | 91.6% | $-5.0M | $-5.6M | $— | — |
| Q1 null | $25.4M | 97.8% | $13.7M | $12.8M | $— | — |
| Q4 2023 | $10.0M | 93.0% | $-1.9M | $-2.8M | $-0.10 | — |